871 related articles for article (PubMed ID: 17510772)
1. Prognostic value of circulating tumor markers in patients with pseudomyxoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Martinetti A; Seregni E; Laterza B; Oliva DG; Deraco M
Ann Surg Oncol; 2007 Aug; 14(8):2300-8. PubMed ID: 17510772
[TBL] [Abstract][Full Text] [Related]
2. Pseudomyxoma peritonei: clinical pathological and biological prognostic factors in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Nonaka D; Langer M; Andreola S; Favaro M; Gavazzi C; Laterza B; Deraco M
Ann Surg Oncol; 2008 Feb; 15(2):526-34. PubMed ID: 18043976
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
Deraco M; Kusamura S; Laterza B; Favaro M; Fumagalli L; Costanzo P; Baratti D
In Vivo; 2006; 20(6A):773-6. PubMed ID: 17203766
[TBL] [Abstract][Full Text] [Related]
4. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Baratti D; Kusamura S; Martinetti A; Seregni E; Oliva DG; Laterza B; Deraco M
Ann Surg Oncol; 2007 Feb; 14(2):500-8. PubMed ID: 17151789
[TBL] [Abstract][Full Text] [Related]
5. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
6. Pseudomyxoma peritonei: biological features are the dominant prognostic determinants after complete cytoreduction and hyperthermic intraperitoneal chemotherapy.
Baratti D; Kusamura S; Nonaka D; Cabras AD; Laterza B; Deraco M
Ann Surg; 2009 Feb; 249(2):243-9. PubMed ID: 19212177
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor markers: predictors of incomplete cytoreduction and powerful determinants of outcome in pseudomyxoma peritonei.
Kusamura S; Hutanu I; Baratti D; Deraco M
J Surg Oncol; 2013 Jul; 108(1):1-8. PubMed ID: 23720095
[TBL] [Abstract][Full Text] [Related]
8. The role of baseline inflammatory-based scores and serum tumor markers to risk stratify pseudomyxoma peritonei patients treated with cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
Kusamura S; Baratti D; Hutanu I; Gavazzi C; Morelli D; Iusco DR; Grassi A; Bonomi S; Virzì S; Haeusler E; Deraco M
Eur J Surg Oncol; 2015 Aug; 41(8):1097-105. PubMed ID: 26026742
[TBL] [Abstract][Full Text] [Related]
9. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution.
Chua TC; Yan TD; Smigielski ME; Zhu KJ; Ng KM; Zhao J; Morris DL
Ann Surg Oncol; 2009 Jul; 16(7):1903-11. PubMed ID: 19387742
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of elevated tumor markers in patients with disseminated appendiceal malignancies treated by cytoreductive surgery and HIPEC.
Ross A; Sardi A; Nieroda C; Merriman B; Gushchin V
Eur J Surg Oncol; 2010 Aug; 36(8):772-6. PubMed ID: 20561764
[TBL] [Abstract][Full Text] [Related]
11. Survival analysis of pseudomyxoma peritonei patients treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg; 2007 Jan; 245(1):104-9. PubMed ID: 17197972
[TBL] [Abstract][Full Text] [Related]
12. Elevated tumour markers prior to complete tumour removal in patients with pseudomyxoma peritonei predict early recurrence.
Alexander-Sefre F; Chandrakumaran K; Banerjee S; Sexton R; Thomas JM; Moran B
Colorectal Dis; 2005 Jul; 7(4):382-6. PubMed ID: 15932563
[TBL] [Abstract][Full Text] [Related]
13. Progression of pseudomyxoma peritonei after combined modality treatment: management and outcome.
Smeenk RM; Verwaal VJ; Antonini N; Zoetmulder FA
Ann Surg Oncol; 2007 Feb; 14(2):493-9. PubMed ID: 17103067
[TBL] [Abstract][Full Text] [Related]
14. Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Dileo P; Laterza B; Deraco M
Ann Surg Oncol; 2009 Feb; 16(2):463-72. PubMed ID: 19082859
[TBL] [Abstract][Full Text] [Related]
15. Treatment of peritoneal carcinomatosis from colonic cancer by cytoreduction, peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC). Experience of ten years.
Vaira M; Cioppa T; D'Amico S; de Marco G; D'Alessandro M; Fiorentini G; De Simone M
In Vivo; 2010; 24(1):79-84. PubMed ID: 20133981
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pseudomyxoma peritonei with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC): a single center experience.
Robella M; Vaira M; Marsanic P; Mellano A; Cinquegrana A; Sottile A; De Simone M
Minerva Chir; 2013 Dec; 68(6):569-77. PubMed ID: 24193289
[TBL] [Abstract][Full Text] [Related]
17. Elevated tumour markers are normalized in most patients with pseudomyxoma peritonei 7 days after complete tumour removal.
Di Fabio F; Aston W; Mohamed F; Chandrakumaran K; Cecil T; Moran B
Colorectal Dis; 2015 Aug; 17(8):698-703. PubMed ID: 25704482
[TBL] [Abstract][Full Text] [Related]
18. Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Deraco M; Nonaka D; Baratti D; Casali P; Rosai J; Younan R; Salvatore A; Cabras Ad AD; Kusamura S
Ann Surg Oncol; 2006 Feb; 13(2):229-37. PubMed ID: 16444562
[TBL] [Abstract][Full Text] [Related]
19. An Italian Multicentric Phase II study on peritonectomy and intra peritoneal hyperthermic perfusion (IPHP) to treat patients with pseudomyxoma peritonei.
Deraco M; De Simone M; Rossi CR; Cavaliere F; Di Filippo F; Vaira M; Piatti P; Kusamura S
J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):35-9. PubMed ID: 16767904
[TBL] [Abstract][Full Text] [Related]
20. Peritoneal pseudomyxoma: results of a systematic policy of complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Elias D; Honoré C; Ciuchendéa R; Billard V; Raynard B; Lo Dico R; Dromain C; Duvillard P; Goéré D
Br J Surg; 2008 Sep; 95(9):1164-71. PubMed ID: 18690633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
